Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Target PharmaSolutions, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Current participant in TARGET-HCC
Adults, age ≥18 years
First diagnosis of HCC (mixed HCC/cholangiocarcinoma may be included). Diagnosis may be histological/cytological and/or radiological.
BCLC Stage A
Underwent, undergoing, or planned to undergo therapy for HCC, with exception that transplant as prior or planned treatment for HCC is excluded.
HCV RNA positive
Continued participation in TARGET-HCC
No recurrence or progression of initial HCC beyond BCLC Stage A prior to Enrollment/Baseline
HCC-free imaging (as defined in Section 9.1.1) at Enrollment/Baseline (see Section 9.2.9 for imaging details; participants may remain in Screening until an HCC-free image is obtained)
Remains DAA-naïve (prior therapy with (peg)IFN and/or ribavirin is allowed)
You may not be if
Inability to provide informed consent
HCC-free imaging (as defined in Section 9.1.1) after treatment of initial HCC prior to Screening (see Section 9.2.9 for imaging details)
Prior liver transplantation
Hepatitis B Virus (HBV) surface antigen positive (HBsAg)
Previously treated with direct-acting antiviral agents (not DAA-naïve); Note that prior (peg)IFN and/or ribavirin therapy is allowed
\- Liver transplantation since Screening
Clareo Health | Direct Acting Antiviral-Post Authorization Safety Study
